Royal Hospital in Oman Introduces AlphaVac System for Advanced Blood Clot Treatment
MUSCAT – June 9, 2025
The Royal Hospital in the Sultanate of Oman has become the first medical institution in the Gulf Cooperation Council (GCC) region to adopt the advanced AlphaVac system, a U.S.-developed technology for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) with minimal invasiveness.
This major milestone reflects the hospital’s commitment to cutting-edge medical innovation and excellence in specialized healthcare services.
Breakthrough in Non-Surgical Clot Removal
The AlphaVac system allows for the rapid and efficient removal of blood clots without the need for open surgery. Using a catheter inserted via the femoral vein under radiological guidance, the system extracts clots in just 30 to 60 minutes with minimal blood loss and complication risks.
Patients typically recover in less than 24 hours and can be discharged from intensive care much sooner than traditional surgical patients.
High Success Rates and Faster Recovery
The hospital’s interventional radiology team reports a success rate exceeding 90% in clot removal using the AlphaVac system, with significantly reduced risks of bleeding and postoperative complications.
The technology offers a safe and effective alternative for patients who are not eligible for surgery or who are at high surgical risk. Many patients have resumed daily activities within days of the procedure, showing a clear improvement in both recovery speed and quality of life.
Part of Oman’s Vision for Medical Excellence
The integration of AlphaVac aligns with the Royal Hospital’s strategic goal to enhance its position as a national referral center and support the Sultanate’s healthcare vision of becoming a regional leader in medical excellence.
“The introduction of AlphaVac reflects our ongoing efforts to provide world-class care and adopt innovative medical solutions,” the medical team stated in an interview with the Oman News Agency.
Conclusion
By becoming the first in the GCC to implement AlphaVac, the Royal Hospital in Muscat sets a new benchmark for minimally invasive clot treatments. This breakthrough not only improves patient outcomes but also strengthens Oman’s position in the global healthcare landscape.
